The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial

What Was Tested

The paper reports a study of Exenatide and Glucagon, published as a randomized controlled trial.

Taspoglutide is a long-acting glucagon-like peptide 1 receptor agonist developed for treatment of type 2 diabetes.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Exenatide study did not mask who received what.

Running at several centres spread the Exenatide study over different clinics and patient groups.

A time span of 24 weeks appears in the methods.

The primary end point was change in HbA(1c) after 24 weeks.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Exenatide, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents, Peptides, Receptors, Glucagon and Venoms.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Exenatide and Glucagon over 24 weeks.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page and the Glucagon compound page, all human trials.